<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>同写意 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-09T11:27:41+08:00</updated>
  <subtitle>一个以新药创制为核心，汇集国内一流研发精英的大型交流与价值分享平台。“同筑技术人生路，写意中国新药魂”是同写意的初衷与愿景。秉承汇集“一线、一流”，讲求“实用、实在、时效”的原则</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>你们是怎么看肿瘤领域新药的？</title>
    <updated>2020-12-09T08:45:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/GS1kqGoaEgupE92aOcvGIw</id>
    <link href="https://mp.weixin.qq.com/s/GS1kqGoaEgupE92aOcvGIw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>写意发布丨东曜药业公布ADC在研药物TAA013Ⅰ期研究结果</title>
    <updated>2020-12-09T08:45:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/oD6cpmXy3WVS_ZeajQPSOQ</id>
    <link href="https://mp.weixin.qq.com/s/oD6cpmXy3WVS_ZeajQPSOQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>会员机构丨乐明药业：乐道秉信，明诚弘毅</title>
    <updated>2020-12-09T08:45:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/m89dQ5ron_t9tLxdBcpl4Q</id>
    <link href="https://mp.weixin.qq.com/s/m89dQ5ron_t9tLxdBcpl4Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亚盛医药董事长杨大俊：解决未被满足的临床需求，首款新药已申请上市</title>
    <updated>2020-12-09T08:45:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/UudSa-TZFwWcW-NsyiQYgw</id>
    <link href="https://mp.weixin.qq.com/s/UudSa-TZFwWcW-NsyiQYgw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>写意云课丨第63期：间充质干细胞外泌体——“神奇药囊”的应用</title>
    <updated>2020-12-09T08:45:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/IcxCyNPBqAdDM3a4VquOVw</id>
    <link href="https://mp.weixin.qq.com/s/IcxCyNPBqAdDM3a4VquOVw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>写意发布丨君圣泰完成数千万美元B+轮融资，加速推进原创新药多个适应症临床II/III期的全球同步开发</title>
    <updated>2020-12-08T08:31:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/-61uFx3ClEYUtjSZa-YxrQ</id>
    <link href="https://mp.weixin.qq.com/s/-61uFx3ClEYUtjSZa-YxrQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>写意报告︱鲍靖：GLP-1受体激动剂的新机遇</title>
    <updated>2020-12-08T08:31:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/SQgmQ4t6bt68sd_pyWCnzg</id>
    <link href="https://mp.weixin.qq.com/s/SQgmQ4t6bt68sd_pyWCnzg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>写意报告︱朱义：全球首个四特异性抗体临床新药研发首次公开报告</title>
    <updated>2020-12-07T18:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/geWm-lONIM_O-5d-tP_Jiw</id>
    <link href="https://mp.weixin.qq.com/s/geWm-lONIM_O-5d-tP_Jiw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>卖，与不卖：沃森生物“反转”背后</title>
    <updated>2020-12-07T18:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/JvNAZSwWlVeLLuIYbrEsIg</id>
    <link href="https://mp.weixin.qq.com/s/JvNAZSwWlVeLLuIYbrEsIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一笔刷历史新高的license out背后，biotech如何跑步进入2.0</title>
    <updated>2020-12-07T18:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/jCeKnFWtHTcTSPJFlMblIg</id>
    <link href="https://mp.weixin.qq.com/s/jCeKnFWtHTcTSPJFlMblIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>写意云课丨第63期：间充质干细胞外泌体——“神奇药囊”的应用</title>
    <updated>2020-12-07T18:15:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/cEz9bJLdbCCIrM_bC1iqrQ</id>
    <link href="https://mp.weixin.qq.com/s/cEz9bJLdbCCIrM_bC1iqrQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科创板咨询委委员、肿瘤专家李进：未来一二级市场重点要投这个方向 ，Top20药企百分之七八十都跟“肿瘤药”有关</title>
    <updated>2020-12-06T18:33:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/P-agZbC78zpx5we9bGuZFg</id>
    <link href="https://mp.weixin.qq.com/s/P-agZbC78zpx5we9bGuZFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>安进CD19/CD3双特异性抗体新药正式在中国获批</title>
    <updated>2020-12-06T18:33:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/eAsumS56Gh7GK2sCsD5T4A</id>
    <link href="https://mp.weixin.qq.com/s/eAsumS56Gh7GK2sCsD5T4A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>跟随性药物：一代新药胜旧药</title>
    <updated>2020-12-06T18:33:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/mv7xDNhpVwb_i5lMUsPJvg</id>
    <link href="https://mp.weixin.qq.com/s/mv7xDNhpVwb_i5lMUsPJvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年终大盘点​！2020年FDA批准的抗癌新药：十大癌症迎来22款新疗法</title>
    <updated>2020-12-06T18:33:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/-Z28w8TTgg6UM83u0tgyJw</id>
    <link href="https://mp.weixin.qq.com/s/-Z28w8TTgg6UM83u0tgyJw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>写意报告丨探讨境外已上市境内未上市化学药品临床研究</title>
    <updated>2020-12-04T19:49:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/1paR0ejrOUg7WfzqJaF9LQ</id>
    <link href="https://mp.weixin.qq.com/s/1paR0ejrOUg7WfzqJaF9LQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【内有福利】赛业大事记丨赛业百沐小动物手术模型表型分析平台隆重开幕</title>
    <updated>2020-12-04T19:49:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/hfQ1GYUIehK8HI-ClmkCAA</id>
    <link href="https://mp.weixin.qq.com/s/hfQ1GYUIehK8HI-ClmkCAA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>美迪西：肿瘤免疫药效评价适合选用哪些模型？</title>
    <updated>2020-12-04T19:49:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/HYGJuFEFUp86bA1chXMTog</id>
    <link href="https://mp.weixin.qq.com/s/HYGJuFEFUp86bA1chXMTog" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDK4/6：First-in-Class年销50亿美元，恒瑞、贝达、君实争相布局</title>
    <updated>2020-12-04T19:49:17+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/mMXzlg-t7Gegy2ZC7STsIg</id>
    <link href="https://mp.weixin.qq.com/s/mMXzlg-t7Gegy2ZC7STsIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>程增江受聘为招商银行特聘专家</title>
    <updated>2020-12-04T19:40:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/vllxlExES7dNQ_d5bfmrYw</id>
    <link href="https://mp.weixin.qq.com/s/vllxlExES7dNQ_d5bfmrYw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>